ImmuniStim (expanded allogeneic γδ T-lymphocytes) / TC Biopharm - LARVOL DELTA

A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19 (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: TC Biopharm | N=12 ➔ 0 | Active, not recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort (PRNewswire) - "TC Biopharm (Holdings) PLC...announced the official dosing of its final patient from the safety cohort for ACHIEVE, its phase 2B clinical trial of OmnImmune® (TCB008) for treatment of Acute Myeloid Leukemia (AML). TC BioPharm's trial involved administering TCB008, the Company's novel drug to treat AML, to pathologically confirmed diagnosed patients afflicted with this type of cancer. The initial 5 patients of the trial were spaced two weeks apart with safety review by an oversight board. This safety cohort is in line with TCBP's stepwise clinical trial advancement, moving from donor matching in the Phase 1b to a universal donor model with no HLA matching of donor to patient. Pending the final review of the Data Safety Monitoring Board (DSMB), the Company will move to open enrolment of the trial, and expect a positive formal review from the DSMB in February."

DSMB • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division (PRNewswire) - "'Our expectation is to file our first IND in the second half of 2023 with additional potential IND submittals for collaborative trials in combination with TCB-008'."

IND • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology

ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB-008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) (clinicaltrials.gov) - P2 | N=148 | Recruiting | Sponsor: TC Biopharm | Not yet recruiting ➔ Recruiting | Initiation date: May 2022 ➔ Aug 2022

Enrollment open • Preclinical • Trial initiation date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB-008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) (clinicaltrials.gov) - P2 | N=148 | Not yet recruiting | Sponsor: TC Biopharm

New P2 trial • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19 (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: TC Biopharm | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Aug 2022 ➔ Nov 2022 | Initiation date: Aug 2021 ➔ Dec 2021 | Trial primary completion date: Aug 2022 ➔ Nov 2022

Enrollment closed • Preclinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

TCB008 in Patients With COVID-19 (clinicaltrials.gov) - P2; N=12; Not yet recruiting; Sponsor: TC Biopharm

New P2 trial • Infectious Disease • Novel Coronavirus Disease